<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04128267</url>
  </required_header>
  <id_info>
    <org_study_id>VICC HN 1982</org_study_id>
    <nct_id>NCT04128267</nct_id>
  </id_info>
  <brief_title>Central Pain Syndrome in Survivors of Head and Neck Cancer</brief_title>
  <official_title>Characterization of Central Pain Syndrome in Survivors of Head and Neck Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt-Ingram Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt-Ingram Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a cross-sectional pilot study of head and neck cancer survivors who have completed&#xD;
      multi-modal treatment to assess and characterize the presence of distinct pain syndromes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary objectives:&#xD;
&#xD;
        -  To correlate structural and functional MRI signature with one of three pain phenotypes&#xD;
           in head and neck cancer survivors: 1) no pain, 2) central pain, and 3) nociceptive pain.&#xD;
&#xD;
        -  To correlate the presence of chronic systemic symptoms with pain phenotype&#xD;
&#xD;
      Exploratory objectives:&#xD;
&#xD;
      - DNA, RNA, and plasma will be collected for genomic, transcriptomic, and proteomic studies.&#xD;
      Results will be vertically integrated along with the results of clinical studies described&#xD;
      within this protocol to identify targets for future correlative studies.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 31, 2019</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Magnetic resonance imaging (MRI) to correlate with one of three pain phenotypes 1) no pain, 2) central pain, 3) nociceptive pain</measure>
    <time_frame>Approximately 8 weeks</time_frame>
    <description>MRI scan of brain to measure response to stimulated pressure to thumbnail</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Magnetic resonance imaging (MRI) to correlate presence of chronic systemic symptoms with pain phenotype</measure>
    <time_frame>Approximately 8 weeks</time_frame>
    <description>MRI scan of brain to measure response to stimulated pressure to thumbnail</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>Response to Pain</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Brain's response to pain using magnetic resonance imaging (MRI)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>IPC-1000</intervention_name>
    <description>Delivers pressure to thumbnail for five seconds at a time</description>
    <arm_group_label>Response to Pain</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Magnetic resonance imaging</intervention_name>
    <description>Scan of brain using Magnetic resonance imaging</description>
    <arm_group_label>Response to Pain</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Correlative Studies</intervention_name>
    <description>Administration of questionnaires via computer</description>
    <arm_group_label>Response to Pain</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with histologically proven head and neck cancer&#xD;
&#xD;
          -  Patients without a diagnosis of head and neck cancer (up to 10 patients, see below)&#xD;
&#xD;
               -  We anticipate enrolling a total of 75 patients with a history of head and neck&#xD;
                  cancer who will complete all questionnaires and MRI scanning. We will also&#xD;
                  recruit up to 10 patients WITHOUT a diagnosis of head and neck cancer to&#xD;
                  facilitate optimization of the MRI scanning processes. This will allow us to&#xD;
                  address logistical issues, such as pressure stimulator setup and timing of each&#xD;
                  scan to be performed.&#xD;
&#xD;
          -  Completed multi-modality therapy a minimum of 6 weeks prior to study entry.&#xD;
&#xD;
          -  Willing and able to provide informed consent&#xD;
&#xD;
          -  All participants must be at least 21 years of age&#xD;
&#xD;
          -  Able to speak English&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who are pregnant&#xD;
&#xD;
          -  Patients who are unable to lie still&#xD;
&#xD;
          -  Patients who are unable tolerate pressure stimulator&#xD;
&#xD;
          -  Non-MRI compatible devices such as aneurysm clips, cardiac pacemakers or&#xD;
             defibrillators, cochlear implants, hardware, or any other implants&#xD;
&#xD;
          -  Iron-based tattoos, pieces of metal (bullet, BB, shrapnel) close to or in an important&#xD;
             organ (such as the eye), or other non-MRI compatible metal in the body&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dianne Lou, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vanderbilt-Ingram Service Information Program</last_name>
    <phone>800-811-8480</phone>
    <email>cip@vanderbilt.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vanderbilt-Ingram Service Information Program</last_name>
      <phone>800-811-8480</phone>
      <email>cip@vumc.org</email>
    </contact>
    <investigator>
      <last_name>Dianne Lou, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>October 14, 2019</study_first_submitted>
  <study_first_submitted_qc>October 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 16, 2019</study_first_posted>
  <last_update_submitted>August 15, 2021</last_update_submitted>
  <last_update_submitted_qc>August 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt-Ingram Cancer Center</investigator_affiliation>
    <investigator_full_name>Dianne Lou</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

